This is the same strategy we recently used for evaluating how medically available drugs influence the expression of PD-L1, and which revealed that prolonged hormone therapy triggers the expression of PD-L1 and PD-L2 in estrogen receptor positive breast cancer cells (Huhn et al. 2022). Here, CD274 is linked to breast carcinoma.